ATE489628T1 - Galk1s als modifikatoren des pten/akt-wegs - Google Patents

Galk1s als modifikatoren des pten/akt-wegs

Info

Publication number
ATE489628T1
ATE489628T1 AT06799955T AT06799955T ATE489628T1 AT E489628 T1 ATE489628 T1 AT E489628T1 AT 06799955 T AT06799955 T AT 06799955T AT 06799955 T AT06799955 T AT 06799955T AT E489628 T1 ATE489628 T1 AT E489628T1
Authority
AT
Austria
Prior art keywords
pten
galk1s
modifiers
akt pathway
akt
Prior art date
Application number
AT06799955T
Other languages
English (en)
Inventor
Arthur Brace
Lynn M Bjerke
Susana Nieto-Bergman
Lori S Friedman
Kevin Ward
Robert A Blake
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Application granted granted Critical
Publication of ATE489628T1 publication Critical patent/ATE489628T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4704—Inhibitors; Supressors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Lock And Its Accessories (AREA)
AT06799955T 2005-06-20 2006-06-20 Galk1s als modifikatoren des pten/akt-wegs ATE489628T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69234205P 2005-06-20 2005-06-20
PCT/US2006/024053 WO2007002131A2 (en) 2005-06-20 2006-06-20 Galk1s as modifiers of the pten/akt pathway and methods of use

Publications (1)

Publication Number Publication Date
ATE489628T1 true ATE489628T1 (de) 2010-12-15

Family

ID=37595741

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06799955T ATE489628T1 (de) 2005-06-20 2006-06-20 Galk1s als modifikatoren des pten/akt-wegs

Country Status (8)

Country Link
US (3) US20100183583A1 (de)
EP (1) EP1898950B1 (de)
JP (1) JP2008543337A (de)
AT (1) ATE489628T1 (de)
AU (1) AU2006262324A1 (de)
CA (1) CA2612224A1 (de)
DE (1) DE602006018461D1 (de)
WO (5) WO2007002088A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8357701B2 (en) 2007-08-15 2013-01-22 University Of Miami Galactokinase inhibitors
EP2254603A4 (de) * 2008-02-25 2012-09-19 Univ Colorado Regents Verfahren zur hemmung von six 1- und eya-proteinen
FR2939355B1 (fr) 2008-12-04 2011-01-07 Seb Sa Appareil electromenager de preparation de jus a rendement de pressage ameliore
BE1018802A3 (nl) 2009-06-29 2011-09-06 Flooring Ind Ltd Sarl Paneel, meer speciaal vloerpaneel.
CN105709217B (zh) * 2014-12-03 2020-04-03 中国科学院上海生命科学研究院 Psat1及其产物在制备调节胰岛素敏感性的药物中的用途
CA3243854A1 (en) * 2022-02-08 2023-08-17 Temple University-Of The Commonwealth System Of Higher Education COMPOSITIONS AND PROCESSES FOR REGENERATION OF CARDIAC TISSUE

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165461A (en) * 1998-04-14 2000-12-26 Board Of Regents, University Of Texas System Tao protein kinases and methods of use therefor
WO2001077150A2 (en) * 2000-04-10 2001-10-18 Merck Patent Gmbh Serine-threonine kinase
AU2001265137B2 (en) 2000-05-30 2007-06-14 Indiana University Research And Technology Corporation Compositions and methods for identifying agents which modulate PTEN function and PI-3 kinase pathways
ATE325889T1 (de) * 2000-07-07 2006-06-15 Eirx Therapeutics Ltd Screening-verfahren
WO2003016549A2 (en) * 2001-08-17 2003-02-27 Incyte Genomics, Inc. Nucleic-acid associated proteins
US20050095592A1 (en) * 2002-02-13 2005-05-05 Jazaeri Amir A. Identification of ovarian cancer tumor markers and therapeutic targets
GB0305267D0 (en) * 2003-03-07 2003-04-09 Eirx Therapeutics Ltd Proteins involved in apoptosis
EP1633856A4 (de) * 2003-06-19 2007-07-18 Exelixis Inc Marks als modifikatoren des pten-wegs und verwendungsverfahren
US20050279317A1 (en) * 2004-06-18 2005-12-22 Leasure Jeremy D Reservoir seal with fluid level indicator

Also Published As

Publication number Publication date
WO2007002131A3 (en) 2007-10-04
WO2007002080A3 (en) 2009-04-30
JP2008543337A (ja) 2008-12-04
WO2007002087A3 (en) 2009-04-16
DE602006018461D1 (de) 2011-01-05
WO2007002131A2 (en) 2007-01-04
WO2007002087A2 (en) 2007-01-04
CA2612224A1 (en) 2007-01-04
WO2007002088A3 (en) 2007-03-29
WO2007002088A2 (en) 2007-01-04
WO2007002080A2 (en) 2007-01-04
EP1898950A4 (de) 2009-02-18
US20100122354A1 (en) 2010-05-13
EP1898950A2 (de) 2008-03-19
EP1898950B1 (de) 2010-11-24
US20110135629A1 (en) 2011-06-09
WO2007002188A3 (en) 2007-05-18
WO2007002188A2 (en) 2007-01-04
US20100183583A1 (en) 2010-07-22
AU2006262324A1 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
GB201021794D0 (en) Treatment and diagnosis of behavioural disorders
DE602006018461D1 (de) Galk1s als modifikatoren des pten/akt-wegs
WO2005016287A3 (en) Prkwnks as modifiers of the rac pathway and methods of use
WO2006009947A3 (en) Migfs as modifiers of the igf pathway and methods of use
WO2005002418A3 (en) Mptens as modifiers of the pten/igf pathway and methods of use
ATE536549T1 (de) Galnts als modifikatoren des igfr-weges und verwendungsverfahren
WO2004104171A3 (en) Ranbp2 as modifier of the pten/igf pathway and methods of use
WO2004024882A3 (en) FLJ20647s AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
EP1723415A4 (de) Pdes als modifikatoren des igfr-wegs und verwendungsverfahren
WO2008036422A3 (en) Vipr1s as modifiers of the e2f/rb pathway and methods of use
WO2006099183A3 (en) Nek8s as modifiers of the pten/akt pathway and methods of use
DE602006021421D1 (de) Ngsverfahren
WO2005090992A3 (en) Mptens as modifiers of the pten pathway and methods of use
WO2006036613A3 (en) Mracs as modifiers of the rac pathway and methods of use
ATE469175T1 (de) Prkcs als modifikatoren des beta catenin pfads und anwendungsverfahren
WO2005017123A3 (en) Mptens as modifiers of the pten pathway and methods of use
WO2007058860A3 (en) Mrhos as modifiers of the rho pathway and methods of use
WO2005072470A3 (en) Mbms as modifiers of branching morphogenesis and methods of use
WO2006009960A3 (en) Hdacs as modifiers of the rb pathway and methods of use
WO2004015071A3 (en) CSNK1GS AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
WO2005001026A3 (en) Adks as modifiers of the pten pathway and methods of use
WO2004083389A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
WO2005123111A3 (en) Maxs as modifiers of the axin pathway and methods of use
WO2004067721A3 (en) Tkts as modifiers of the beta-catenin pathway and methods of use
WO2004067722A3 (en) Facls as modifiers of the rb pathway and methods of use

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties